# MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Source: https://onco.cc/key-papers/paper-elad-cancer/  
OnCo record `paper-elad-cancer` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by four technology pages, indexed on Europe PMC as PubMed record 32786044 and published in Cancer; the citing pages link this DOI, which is how the record was matched.

## Summary

Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis.

Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.

Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions.

Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.

Indexed on Europe PMC as PubMed record 32786044 (DOI 10.1002/cncr.33100). Matched by DOI alone: four technology pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Cancer
- Year: 2020
- DOI: 10.1002/cncr.33100
- Authors: Elad S, Cheng KKF, Lalla RV, et al.
- What it means: Four technology pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Cancer 2020: https://doi.org/10.1002/cncr.33100
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32786044/
- Europe PMC: https://europepmc.org/article/MED/32786044

## Connected records

- technologies: [Glutamine for mucositis and neuropathy](https://onco.cc/technologies/glutamine-mucositis-neuropathy/), [Honey for radiation mucositis](https://onco.cc/technologies/honey-radiation-mucositis/), [Oral cryotherapy (ice chips) to prevent mucositis](https://onco.cc/technologies/oral-cryotherapy-mucositis/), [Photobiomodulation (low-level laser) for oral mucositis](https://onco.cc/technologies/photobiomodulation-mucositis/)
- journals: [Cancer](https://onco.cc/journals/cancer-wiley/)

---
JSON: https://onco.cc/api/v1/entities/paper-elad-cancer.json